Results 91 to 100 of about 31,891 (279)
ABSTRACT Background Stage II endometrial cancer comprises 5% to 10% of cases and is pathologically diverse. Retrospective data guides recommendations which suggest surgical staging with adjuvant therapy, but the role of radical surgery and lymphadenectomy is uncertain, due to conflicting outcomes.
Jonathan Sandeford+2 more
wiley +1 more source
Advances in breast cancer treatment and prevention: preclinical studies on aromatase inhibitors and new selective estrogen receptor modulators (SERMs). [PDF]
Intensive basic and clinical research over the past 20 years has yielded crucial molecular understanding into how estrogen and the estrogen receptor act to regulate breast cancer and has led to the development of more effective, less toxic, and safer ...
Brown, Powel H+2 more
core +2 more sources
Immune checkpoint inhibitors (ICIs) have been a breakthrough in cancer therapy, inducing durable remissions in responding patients. However, they are associated with variable outcomes, spanning from disease hyperprogression to complete responses with the onset of immune‐related adverse events.
Mikhaël Attias, Ciriaco A. Piccirillo
wiley +1 more source
Supplementary Figure 5 from Omental Adipose Tissue–Derived Stromal Cells Promote Vascularization and Growth of Endometrial Tumors [PDF]
Ann H. Klopp+11 more
openalex +2 more sources
Reporting clinical cases of high-grade endometrial stromal sarcoma tumors is essential for a better understanding of their natural course and for the development of appropriate diagnostic and treatment strategies.
Faraz Mahdizadeh+3 more
doaj +1 more source
Endometrial stromal sarcomas (ESSs) are rare malignant tumors of the uterus that arise from the endometrial stroma, the annual incidence of ESS being 1–2/million women.
Meenakshi Gothwal+4 more
doaj +1 more source
ABSTRACT Claudin 18.2 (CLDN18.2), a tight junction protein isoform, is an emerging therapeutic target in oncology. CLDN18 is well‐characterized in gastric cancer, but its pan‐cancer expression profiles and isoform distributions are poorly documented.
Tadayoshi Hashimoto+28 more
wiley +1 more source
A Case Report of a Severely Aggressive Uterine Sarcoma at an Unusual Age [PDF]
Uterine sarcomas are very unique tumors with mesodermial origin and accounting for 2-6% of uterine cancers. In general, uterine sarcomas are the most malignant tumors of the uterus.
zahra honarvar, Mohades Peydayesh
doaj
Uterine lesions with sex cord-like architectures: a systematic review
Background Sex cord-like elements are rarely observed in uterine lesions, but these morphological patterns could appear in a variety of uterine tumors and non-tumorous lesions.
Meng Jia, Ping-Li Sun, Hongwen Gao
doaj +1 more source
Diagnostic evaluation of metastatic rhabdomyosarcoma in effusion specimens [PDF]
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/100330/1/dc22987 ...
Afify+15 more
core +1 more source